Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
Further Reading from MarketBeat Media
What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller. Article Posted: 5/7/2026. 
Key Points
- Eli Lilly has been clearly winning its GLP-1 battle against Novo Nordisk, but both companies just got a piece of good news
- The Food and Drug Administration's latest proposal looks to curtail certain compounding facilities going forward
- Shares of LLY, NVO, and HIMS all gained on the day of the announcement
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are two weight-loss and diabetes drug stocks that have followed completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has fallen more than 30%. This reflects the massive market share Eli Lilly has taken from Novo. In its latest quarter, Eli Lilly posted revenue growth of 56% year over year (YOY). For full-year 2026, the midpoint of Lilly’s guidance implies growth of 28% YOY.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
Meanwhile, Novo expects constant-currency sales to fall by 5% to 13% YOY in 2026, a steep decline from growth of 36% in 2023. Much of the gap between the two companies is due to Lilly’s GLP-1 tirzepatide. Branded as Mounjaro and Zepbound, the drug induces around 47% more weight loss than Novo’s semaglutide. Despite their competition, both companies recently received news they can cheer about. The Food and Drug Administration has proposed excluding tirzepatide and semaglutide from its 503B bulk list. Here’s what that could mean for Lilly and Novo going forward. FDA Looks to Stop 503B Compounding for Good—Lilly and Novo ScoreWhen an approved drug is in shortage, the FDA allows 503A compounding pharmacies and 503B outsourcing facilities to compound copies of the drug. After the FDA added tirzepatide and semaglutide to the shortage list in 2022, companies like Hims & Hers Health built businesses around compounding GLP-1s. Hims has used both 503A and 503B facilities to source its drugs in the past. Shortages for both drugs ended between 2024 and 2025, but Hims operated in a legal gray area to continue selling them. According to Pharmacy Times, if the proposal is adopted, it would “foreclose any future pathway” for 503B facilities to compound the drugs, “even in the event of a new shortage designation.” In other words, there would be no going back. For Lilly and Novo, that would be a clear win. Compounders have siphoned off demand for their drugs that would otherwise have gone to the two companies. The proposal would remove the ability of 503B facilities to do that in the future. For 503A facilities, that future opportunity still exists, although selling these drugs under that status is technically prohibited now that the shortages are over. Still, Hims clearly demonstrates that regulators have not fully enforced this. Notably, Novo shares rose 4.8% on the day of the April 30 announcement, showing that investors viewed it as a meaningful piece of positive news. Lilly rose 9.8% that day, and while the announcement coincided with the company’s highly impressive earnings report, the news likely contributed to Lilly’s strong gain as well. Hims Gains as Investors Weigh Compounding RegulationFor Hims and Hers, the benefit is more nuanced but still real. The company recently signed a deal with Novo, allowing it to formally sell semaglutide and oral semaglutide. Under this proposal, the group of compounders Hims competes with would be weakened. With its Novo agreement, Hims can sell branded (AKA non-compounded) versions of the company’s GLP-1s. That means the FDA proposal should not limit Hims' ability to sell Novo’s drugs. However, it would affect the ability of some compounders to do the same in the future, putting Hims in a stronger position. In a statement to Reuters, a Hims & Hers spokesperson said the company does not expect the proposal to impact its business. Hims noted that “there are no GLP‑1s compounded by 503B facilities accessible through our platform.” Hims shares rose by approximately 3.2% on the day of the proposal. Hims can also continue to sell Lilly’s drugs. However, the firm does not have the same type of agreement with Lilly that it does with Novo. Accessing Lilly’s drugs through Hims acts more like a referral arrangement, directing users to Lilly. Hims' own announcement says, “Access to Zepbound and Foundayo does not imply a partnership or affiliation with Eli Lilly and Company." Because of this, it is very unlikely that Hims receives any direct financial benefit from offering Lilly’s drugs. However, Hims may be able to gain or retain members who would have otherwise turned to other telehealth platforms to access Lilly’s treatments. Lilly Continues to Dominate the GLP-1 ArenaOverall, Eli Lilly and Novo should receive added protection for their valuable GLP-1 drugs. The proposal is not final yet. However, because it came from the FDA itself, it is likely to be enacted. Hims is an under-the-radar winner from the proposal on the semaglutide side, given its formally established relationship with Novo. However, among these names, Eli Lilly is clearly in the strongest position. The company has shown that it doesn’t need to make a deal with Hims like Novo did. Instead, it is capturing the full benefit of its top-performing weight-loss and diabetes medications. |
0 Response to "Your insider updates are waiting"
Post a Comment